Login / Signup

Combined pre-treatment and middle-treatment Epstein-Barr virus DNA load contributes to prognostication and treatment modification in nasopharyngeal carcinoma patients.

Kaiqi LanJingrong MaoXuesong SunSuchen LiSiyi XieRui SunSailan LiuHai-Qiang Mai
Published in: Therapeutic advances in medical oncology (2024)
cisplatin may be adequate to achieve satisfactory survival outcomes in the high-risk group.
Keyphrases
  • epstein barr virus
  • end stage renal disease
  • chronic kidney disease
  • newly diagnosed
  • diffuse large b cell lymphoma
  • combination therapy
  • single molecule
  • cell free
  • patient reported outcomes
  • nucleic acid